Amp C β-lactamase-producing Escherichia coli in neonatal meningitis

Diagnostic and therapeutic challenge

E. Fakioglu, A. M. Queenan, K. Bush, S. G. Jenkins, Betsy Herold

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Antibiotic resistance is a global health priority. Major defenses for Gram-negative bacteria are β-lactamase enzymes, which have co-evolved with the development and increasing utilization of new antibiotics. Bacteria harboring the plasmid-mediated AmpC enzymes are increasingly prevalent among adult patients, but have not previously been reported in neonates. Early-onset neonatal meningitis caused by an AmpC β-lactamase-producing Escherichia coli is described for the first time; the plasmid was identified as a transferable CMY-2 family β-lactamase. Limited experience with newer antibiotics and pharmacokinetics in neonates presents a therapeutic challenge. Currently, there are no Clinical Laboratory Standards Institute (CLSI) recommendations for detecting AmpC nor is the optimal treatment for AmpC-producing organisms known. Thus, it is imperative that clinicians have a high index of suspicion when antimicrobial susceptibility patterns are inconsistent. Development of better microbiology screening tests to rapidly detect resistance is essential. Additionally, pharmacokinetic studies with newer antibiotics in neonates are warranted.

Original languageEnglish (US)
Pages (from-to)515-517
Number of pages3
JournalJournal of Perinatology
Volume26
Issue number8
DOIs
StatePublished - Aug 2006
Externally publishedYes

Fingerprint

Meningitis
Newborn Infant
Escherichia coli
Anti-Bacterial Agents
Plasmids
Pharmacokinetics
Health Priorities
Enzymes
Microbial Drug Resistance
Microbiology
Gram-Negative Bacteria
Therapeutics
Bacteria

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Pediatrics, Perinatology, and Child Health

Cite this

Amp C β-lactamase-producing Escherichia coli in neonatal meningitis : Diagnostic and therapeutic challenge. / Fakioglu, E.; Queenan, A. M.; Bush, K.; Jenkins, S. G.; Herold, Betsy.

In: Journal of Perinatology, Vol. 26, No. 8, 08.2006, p. 515-517.

Research output: Contribution to journalArticle

Fakioglu, E. ; Queenan, A. M. ; Bush, K. ; Jenkins, S. G. ; Herold, Betsy. / Amp C β-lactamase-producing Escherichia coli in neonatal meningitis : Diagnostic and therapeutic challenge. In: Journal of Perinatology. 2006 ; Vol. 26, No. 8. pp. 515-517.
@article{f5ce41fd963849d6bdf9884ed620f18c,
title = "Amp C β-lactamase-producing Escherichia coli in neonatal meningitis: Diagnostic and therapeutic challenge",
abstract = "Antibiotic resistance is a global health priority. Major defenses for Gram-negative bacteria are β-lactamase enzymes, which have co-evolved with the development and increasing utilization of new antibiotics. Bacteria harboring the plasmid-mediated AmpC enzymes are increasingly prevalent among adult patients, but have not previously been reported in neonates. Early-onset neonatal meningitis caused by an AmpC β-lactamase-producing Escherichia coli is described for the first time; the plasmid was identified as a transferable CMY-2 family β-lactamase. Limited experience with newer antibiotics and pharmacokinetics in neonates presents a therapeutic challenge. Currently, there are no Clinical Laboratory Standards Institute (CLSI) recommendations for detecting AmpC nor is the optimal treatment for AmpC-producing organisms known. Thus, it is imperative that clinicians have a high index of suspicion when antimicrobial susceptibility patterns are inconsistent. Development of better microbiology screening tests to rapidly detect resistance is essential. Additionally, pharmacokinetic studies with newer antibiotics in neonates are warranted.",
author = "E. Fakioglu and Queenan, {A. M.} and K. Bush and Jenkins, {S. G.} and Betsy Herold",
year = "2006",
month = "8",
doi = "10.1038/sj.jp.7211550",
language = "English (US)",
volume = "26",
pages = "515--517",
journal = "Journal of Perinatology",
issn = "0743-8346",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Amp C β-lactamase-producing Escherichia coli in neonatal meningitis

T2 - Diagnostic and therapeutic challenge

AU - Fakioglu, E.

AU - Queenan, A. M.

AU - Bush, K.

AU - Jenkins, S. G.

AU - Herold, Betsy

PY - 2006/8

Y1 - 2006/8

N2 - Antibiotic resistance is a global health priority. Major defenses for Gram-negative bacteria are β-lactamase enzymes, which have co-evolved with the development and increasing utilization of new antibiotics. Bacteria harboring the plasmid-mediated AmpC enzymes are increasingly prevalent among adult patients, but have not previously been reported in neonates. Early-onset neonatal meningitis caused by an AmpC β-lactamase-producing Escherichia coli is described for the first time; the plasmid was identified as a transferable CMY-2 family β-lactamase. Limited experience with newer antibiotics and pharmacokinetics in neonates presents a therapeutic challenge. Currently, there are no Clinical Laboratory Standards Institute (CLSI) recommendations for detecting AmpC nor is the optimal treatment for AmpC-producing organisms known. Thus, it is imperative that clinicians have a high index of suspicion when antimicrobial susceptibility patterns are inconsistent. Development of better microbiology screening tests to rapidly detect resistance is essential. Additionally, pharmacokinetic studies with newer antibiotics in neonates are warranted.

AB - Antibiotic resistance is a global health priority. Major defenses for Gram-negative bacteria are β-lactamase enzymes, which have co-evolved with the development and increasing utilization of new antibiotics. Bacteria harboring the plasmid-mediated AmpC enzymes are increasingly prevalent among adult patients, but have not previously been reported in neonates. Early-onset neonatal meningitis caused by an AmpC β-lactamase-producing Escherichia coli is described for the first time; the plasmid was identified as a transferable CMY-2 family β-lactamase. Limited experience with newer antibiotics and pharmacokinetics in neonates presents a therapeutic challenge. Currently, there are no Clinical Laboratory Standards Institute (CLSI) recommendations for detecting AmpC nor is the optimal treatment for AmpC-producing organisms known. Thus, it is imperative that clinicians have a high index of suspicion when antimicrobial susceptibility patterns are inconsistent. Development of better microbiology screening tests to rapidly detect resistance is essential. Additionally, pharmacokinetic studies with newer antibiotics in neonates are warranted.

UR - http://www.scopus.com/inward/record.url?scp=33746526033&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746526033&partnerID=8YFLogxK

U2 - 10.1038/sj.jp.7211550

DO - 10.1038/sj.jp.7211550

M3 - Article

VL - 26

SP - 515

EP - 517

JO - Journal of Perinatology

JF - Journal of Perinatology

SN - 0743-8346

IS - 8

ER -